Keywords: positive, data, glivec, early, gist, study, swiss

Positive data for Glivec in early GIST study

Article | 23 April 2007

Print This

Swiss drug major Novartis says that the interim analysis of data from a study of its anticancer agent Glivec (imatinib) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in